reports
STRATA Skin Sciences Showcases XTRAC® and TheraclearX® at TeraCILAD 20...
STRATA Skin Sciences Showcases XTRAC® and TheraclearX® at TeraCILAD 2025 — Reports Early Adoption Momentum in Mexico HORSHAM, Pa., Dec. 09, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a global leader in in-office dermatologic technologies, announces its participation in the 2025 Ibero-Latin American Congress of Dermatology (TeraCILAD) November 19-22, 2025, where it presented its XTRAC® excimer laser and TheraclearX® acne therapy system. STRATA also reported that, by the end of 2025, there will be over 12 new recurring TheraclearX® accounts in Mexico, reflecting gro...
Strata Skin Sciences Inc: 1 director
A director at Strata Skin Sciences Inc sold/bought 19,094 shares at 1.334USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last tw...
STRATA Skin Sciences Reports Third Quarter 2025 Financial Results and ...
STRATA Skin Sciences Reports Third Quarter 2025 Financial Results and Provides a Corporate Update HORSHAM, Penn., Nov. 13, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces its financial results for the quarter ended September 30, 2025, and provides a corporate update. Third Quarter Highlights Continued progress toward historic expansion of CPT codes for reimbursement for inflammator...
STRATA Skin Sciences Announces CMS Recognition of Expanded CPT Codes f...
STRATA Skin Sciences Announces CMS Recognition of Expanded CPT Codes for Inflammatory and Autoimmune Dermatologic Conditions with Company Anticipating Wider Excimer Adoption Ahead Of 2027 CPT Expansion Higher reimbursement, regulatory clarity, and acknowledgment of future indication expansion expected to reinforce physician confidence and support continued expansion HORSHAM, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a global leader in excimer laser therapy for inflammatory and autoimmune dermatologic diseases, today announced that the Centers for ...
STRATA Skin Sciences to Report Third Quarter 2025 Financial Results on...
STRATA Skin Sciences to Report Third Quarter 2025 Financial Results on November 13, 2025 and Provide Corporate Update HORSHAM, Penn., Nov. 05, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that it will report third quarter 2025 financial results on Thursday, November 13, 2025 after the market close. STRATA management will subsequently host a conference call at 4:30 p.m. ET on Thur...
STRATA Skin Sciences Announces COFEPRIS Clearance of TheraClear® in Me...
STRATA Skin Sciences Announces COFEPRIS Clearance of TheraClear® in Mexico and First Commercial Placements HORSHAM, Pa., Oct. 28, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a global leader in in-office dermatologic technologies for the treatment of skin conditions such as acne, psoriasis, and vitiligo, today announced that its TheraClearX® acne treatment system has received regulatory clearance from the Mexican health authority, COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios), under Device Registration No. 3187E2024SSA, valid through Novem...
STRATA Skin Sciences Reinforces Market Leadership Following Key Litiga...
STRATA Skin Sciences Reinforces Market Leadership Following Key Litigation Milestones Against LaserOptek HORSHAM, Penn., Oct. 20, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, today provided an update on its competitive positioning and ongoing litigation against LaserOptek America Corp., LaserOptek Co. Ltd. (“LaserOptek Korea”), and affiliated entities including The Pinnacle Health Group and...
Excimer Laser Demonstrates Promising Results in Treating Rare Variant ...
Excimer Laser Demonstrates Promising Results in Treating Rare Variant of Cutaneous Lymphoma, Mycosis Fungoides First English-language case study shows resolution of lesions with 308-nm Excimer laser in rare mycosis fungoides (MF) subtype, poikilodermatous mycosis fungiodes (pMF), underscoring the Company’s XTRAC capability to address the condition HORSHAM, Pa., Oct. 14, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of...
Marking Eczema Awareness Month – Clinical Research Validates Strata Sk...
Marking Eczema Awareness Month – Clinical Research Validates Strata Skin Sciences’ XTRAC® Excimer Laser as a Breakthrough Therapy for Localized Atopic Dermatitis HORSHAM, Pa., Oct. 03, 2025 (GLOBE NEWSWIRE) -- In recognition of Eczema Awareness Month, STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, highlights the substantial body of peer-reviewed clinical evidence supporting the XTRAC® Excimer Laser (308 nm) as a safe...
STRATA Skin Sciences Receives Continued Validation for its Personalize...
STRATA Skin Sciences Receives Continued Validation for its Personalized Approach with New Published Study Highlighting XTRAC® Excimer Laser Treatment Combined with a Topical Drug in Psoriasis HORSHAM, Pa., Sept. 30, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces the publication of a new peer-reviewed study in Lasers in Medical Science that reinforces the Company’s commitment to pers...
STRATA Skin Sciences Announces Closing of $2.42 Million Registered Dir...
STRATA Skin Sciences Announces Closing of $2.42 Million Registered Direct Offering HORSHAM, Pa., Sept. 04, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (Nasdaq: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, today announced the closing of its previously announced registered direct offering for the issuance and sale of 1,097,547 shares of the Company’s common stock at a per share purchase price of $2.204. Ladenburg Thalmann & Co. Inc. acted as e...
STRATA Skin Sciences’ Elevate 360 Consulting Offering Drives Growth in...
STRATA Skin Sciences’ Elevate 360 Consulting Offering Drives Growth in Partner Clinic Operations and Fuels New Partnership Agreements Consulting program optimizes partner clinic businesses with implementation of best practices initiatives, including marketing, reimbursement, and patient retention HORSHAM, Pa., Sept. 04, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces growth in busi...
STRATA Skin Sciences Announces Pricing of $2.42 Million Registered Dir...
STRATA Skin Sciences Announces Pricing of $2.42 Million Registered Direct Offering of Common Stock Priced At-Market Under Nasdaq Rules HORSHAM, Pa., Sept. 03, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, today announced that it has entered into definitive securities purchase agreements with certain institutional investors for the purchase and sale of 1,097,547 shares of the Company’s common...
STRATA Skin Sciences to Present at the H.C. Wainwright 27th Annual Glo...
STRATA Skin Sciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference HORSHAM, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that Dr. Dolev Rafaeli, President and CEO of Strata Skin Sciences will present a corporate overview at the H.C. Wainwright 27th Annual Global Investment Conference. The conference is being held on September 8 – 10, 202...
STRATA Skin Sciences IP Portfolio Holds Exclusivity in Combination The...
STRATA Skin Sciences IP Portfolio Holds Exclusivity in Combination Therapies of Its XTRAC Excimer Laser with JAK Inhibitors, Systemic and Biologic Drugs, Bolstering Expansion into New Indications Like Vitiligo and Other Auto-Immune Skin Conditions Strata continues to work closely with CMS to ensure a rapid implementation of the extended codes HORSHAM, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of de...
STRATA Skin Sciences Reports Second Quarter 2025 Financial Results and...
STRATA Skin Sciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update HORSHAM, Penn., Aug. 13, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces its financial results for the quarter ended June 30, 2025, and provides a corporate update. Second Quarter Highlights Historic expansion of CPT codes for reimbursement for inflammatory and auto-immune skin diseas...
STRATA Skin Sciences Moves to Accelerate Medicare and Private Payer Co...
STRATA Skin Sciences Moves to Accelerate Medicare and Private Payer Coverage from Expanded CPT Code Expansion, Tripling Addressable Market to 30M+ Patients Peer-reviewed publications continue to validate Excimer Laser efficacy in vitiligo and treatment STRATA updates status of non-Excimer laser false advertising litigation HORSHAM, Pa., Aug. 07, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditio...
STRATA Skin Sciences to Report Second Quarter 2025 Financial Results o...
STRATA Skin Sciences to Report Second Quarter 2025 Financial Results on August 13, 2025 and Provide Corporate Update HORSHAM, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that it will report second quarter 2025 financial results on Wednesday, August 13, 2025 after the market close. STRATA management will subsequently host a conference call at 4:30 p.m. ET on Wedne...
STRATA Skin Sciences Announces Historic Expansion of CPT Codes for Rei...
STRATA Skin Sciences Announces Historic Expansion of CPT Codes for Reimbursement of 308nm Excimer Laser Treatments, Unlocking Access for Millions with Inflammatory and Auto-Immune Skin Diseases HORSHAM, Pa., May 19, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to advancing dermatologic care through innovation, announces that the American Medical Association (AMA) CPT Editorial Panel, in its May, 2025 summary of panel actions () has accepted revision to CPT codes 96920-96922, expanding reimbursement e...
STRATA Skin Sciences Reports First Quarter 2025 Financial Results and ...
STRATA Skin Sciences Reports First Quarter 2025 Financial Results and Provides a Corporate Update HORSHAM, Pa., May 14, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces its financial results for the quarter ended March 31, 2025, and provides a corporate update. First Quarter 2025 Financial Highlights Revenue in the first quarter of 2025 was $6.8 million, up 1% Global net recurring X...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.